SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001213900-26-057939
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026057939/ea0290954-s1_synergy.htm

Chunk 5 of 16
Word Count: 1425
Character Count: 9020

Document Content:

generally accepted in the United States (“U.S. GAAP”), provides useful information to investors. Year Ended December 31, 2025 Year Ended December 31, 2024 Net income $ (12,341,208 ) $ 2,124,976 Interest income (15,065 ) (1,523 ) Interest expense 5,919,742 4,105,198 Income tax expense 117,471 102,085 Depreciation and amortization 133,334 133,334 EBITDA $ (6,185,726 ) $ 6,464,070 EBITDA is considered a non-GAAP financial measure. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definition of EBITDA might not be comparable to similarly titled measures reported by other companies. Summary Risk Factors An investment in our common stock involves a high degree of risk. You should carefully consider the risks summarized below. These risks are discussed more fully in the section titled “Risk Factors” following this prospectus summary and under similar headings in the documents incorporated by reference into this prospectus. These risks include, but are not limited to, the following:

●	We operate in a highly competitive industry and our failure
to compete effectively could materially and adversely affect our sales and growth prospects;

●	Our failure to appropriately respond to changing consumer preferences
and demand for new products or product enhancements could significantly harm our relationship with customers and our product sales, as
well as our financial condition and operating results;

●	Our sales growth is dependent upon maintaining our relationships
with a small number of existing large customers, and the loss of any one such customer could materially adversely affect our business
and financial performance;

●	If our outside suppliers and manufacturers fail to supply products
in sufficient quantities and in a timely fashion, our business could suffer;

●	Adverse or negative publicity could cause our business to suffer;

●	We continue to explore new strategic initiatives, but we may
not be able to successfully execute on, or realize the expected benefits from, the implementation of our strategic initiatives, and our
pursuit of new strategic initiatives may pose significant costs and risks;

●	The nutritional supplement industry increasingly relies on intellectual
property rights and although we seek to ensure that we do not infringe the intellectual property rights of others, there can be no assurance
that third parties will not assert intellectual property infringement claims against us;

●	We plan to expand into additional international markets, which
will expose us to significant operational risks;

●	We may experience product recalls, withdrawals or seizures,
which could materially and adversely affect our business, financial condition and results of operations;

●	We and our suppliers are subject to numerous laws and regulations
that apply to the manufacturing and sale of nutritional supplements, and compliance with these laws and regulations, as they currently
exist or as modified in the future, may increase our costs, limit or eliminate our ability to sell certain products, subject us or our
suppliers to the risk of enforcement action or litigation, or otherwise adversely affect our business, results of operations and financial
condition; and

●	The other factors described in “ Risk Factors .”

Implications of Being a Smaller Reporting Company

We are a “smaller reporting
company” as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting
companies so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250.0 million
measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most
recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0 million measured
on the last business day of our second fiscal quarter.

Corporate Information

We were organized as a corporation
under the laws of the State of Nevada on December 29, 2010 under the name “Oro Capital Corporation.” In April 2014,
Synergy Strips Corp., a Delaware corporation, became our wholly-owned subsidiary, and we changed our name from “Oro Capital
Corporation” to “Synergy Strips Corp.” In August 2015, we changed our name to “Synergy CHC Corp.” In
January 2019, our other U.S. subsidiaries, Neuragen Corp., Sneaky Vaunt Corp., The Queen Pegasus Corp. and Breakthrough Products
Inc., merged with and into the Company. Synergy is the sole owner of four subsidiaries: NomadChoice Pty Ltd., Hand MD Corp., Synergy CHC
Inc. and Synergy CHC Mexico, and the results have been consolidated in these statements. Synergy CHC Mexico was incorporated during May
2025 for the purposes of expanding into Mexico.

We completed our initial public
offering on October 24, 2024, and became subject to the information and reporting requirements of the Exchange Act. We file
periodic reports, proxy statements and other information with the SEC.

The address of our principal
executive offices is currently 770 Roosevelt Trail STE 8 #1016, N. Windham, Maine 04062 and our phone number is (207) 321-2350. Our
website is www.synergychc.com. The information contained in, or that can be accessed through, our website is not incorporated
by reference in, and is not part of, this prospectus.

The Offering

Securities Offered by Selling Stockholder ●	up to 100,000,000 ELOC Shares;

●	up to 1,540,000 Warrant Shares; and

●	170,000 Existing Shares.

Shares of common stock outstanding prior to this offering 14,899,883 shares.

Common stock to be outstanding after this offering 116,439,883 shares assuming the sale of all of the ELOC Shares and
Warrant Shares registered under the Registration Statement. The actual number of shares issued will vary depending on the sales prices
in this offering, but will not be greater than 2,978,486 shares (including the Warrant Shares), representing 19.99% of the shares of our
common stock outstanding on the date of the ELOC Purchase Agreement (the “Exchange Cap”), unless we first obtain stockholder
approval to issue shares in excess of such amount under the ELOC Purchase Agreement.

Terms of the Offering The Selling Stockholder and any of their pledgees, assignees and successors-in-interest
will determine when and how they sell the shares offered in this prospectus and may, from time to time, sell any or all of their shares
of common stock covered hereby on Nasdaq or any other stock exchange, market or trading facility on which the shares are traded or in
privately negotiated transactions. These sales may be at fixed or negotiated prices. For more information, see the section of this prospectus
entitled “ Plan of Distribution ” beginning on page 16.

Use of Proceeds The Selling Stockholder will receive all
of the proceeds from the sale of the shares of common stock offered for sale by it under this prospectus. We will not receive proceeds
from the sale of the shares of common stock by the Selling Stockholder.

We may receive up to $36,000,000 in aggregate
gross proceeds under the ELOC Purchase Agreement in connection with sales of our shares of common stock to the Selling Stockholder that
we may, in our discretion, elect to make, from time to time pursuant to the ELOC Purchase Agreement after the date of this prospectus.
We intend to use the proceeds from the sale of our shares of common stock to the Selling Stockholder for general corporate purposes.
Our management will have broad discretion over the use of proceeds from the sale of our shares of common stock under the ELOC Purchase
Agreement.

For more information, see the section of this
prospectus entitled “ Use of Proceeds ” beginning on page 10.

Risk Factors You should read the “ Risk Factors ” section of this prospectus beginning on page 9 of this prospectus and under similar headings in the documents incorporated by reference into this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.

Nasdaq Capital Market Symbol SNYR

Transfer Agent and Registrar VStock Transfer, LLC

As of May 14, 2026, 15,079,956 shares
of our common stock were issued and 14,899,883 shares were outstanding. Unless we indicate otherwise or the context otherwise requires,
all information in this prospectus:

●	does not reflect 1,540,000 Warrant Shares issuable upon the exercise
of the Warrant at an exercise price of $0.01 per share;

●	does not reflect 1,200,000 shares of common stock issuable upon
the exercise of outstanding options at a weighted average exercise price of $2.38 per share;

●	does not reflect 2,252,102 shares of common stock reserved for
future issuance pursuant to the Synergy CHC Corp. 2024 Equity Incentive Plan (the “2024 Equity Incentive Plan”); and

●	does not reflect 3,156,000 shares of common stock issuable upon
the exercise of outstanding warrants at a weighted average exercise price of $0.43 per share.

RISK FACTORS